Finasteride is the most evidence-backed pharmaceutical option for male pattern hair loss - and it's also the medication that drives the loudest side-effect conversation on the internet. The data behind PSSD (post-finasteride syndrome) deserves an honest read, not a marketing pitch in either direction. Here's the real picture, the alternatives, and the informed-consent standard we hold.
How finasteride actually works
Finasteride inhibits 5-alpha reductase type 2, blocking conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen driving androgenetic alopecia (AGA) at the follicle level. Lower DHT, slower hair miniaturization.
Standard dose: 1 mg/day oral (Propecia) for AGA; 5 mg/day (Proscar) for benign prostatic hyperplasia. Topical finasteride 0.25% formulations are emerging with lower systemic exposure - data is promising but smaller in scale.
Effect timeline: shedding can increase in the first 8-12 weeks (regrowth phase), visible stabilization by 6 months, peak benefit at 12-24 months. Stopping reverses gains within 6-12 months.
What the side-effect data actually shows
Sexual side effects in randomized trials (libido, erectile, ejaculatory): roughly 1.4-3.8% on finasteride vs 1.0-2.3% on placebo. Real, but modest in absolute terms. Most resolve within weeks of stopping.
PSSD (post-finasteride syndrome): persistent sexual, neurological, or psychological symptoms after discontinuation. Documented in case series and patient registries; underlying mechanism debated; absolute incidence unclear (estimates range 0.1-2% depending on source, with significant reporting bias).
Risk of high-grade prostate cancer: REDUCE trial showed a small absolute increase (0.8% vs 0.5%) - whether this reflects detection bias or biology is still debated. We discuss this with anyone over 40 considering finasteride.
Alternatives and stacking
Topical minoxidil 5% (men) or 2-5% (women): the most-tolerated first-line, ~30-40% see meaningful regrowth at 6 months. Different mechanism (vasodilation/anagen extension), can be stacked with finasteride.
Oral minoxidil low-dose (1.25-5 mg): emerging as an effective option, especially when topical irritates the scalp. Side effects: hypertrichosis (extra body hair), occasional ankle edema. Requires provider review.
Topical ketoconazole 2%, microneedling, dutasteride (stronger 5-AR inhibitor, more sustained side effects), platelet-rich plasma (PRP) injections - varying evidence, often combined. Spironolactone is the analog for women, not men.
Informed consent that actually informs
Anyone prescribing finasteride without a 15-minute conversation about side-effect data, the persistent-symptom literature, and alternatives is dispensing a medication, not practicing medicine. We won't write the prescription that way.
Baseline labs: total T, free T, estradiol, PSA. We retest at 6 months and check in on libido, mood, and erectile function. Side effects flagged early get a dose drop, switch to topical, or stop - not a "push through" plan.
Stopping is always on the table. Persistent symptoms after discontinuation are rare but real, and they're not psychosomatic. We do not minimize PSSD reports.
What to do now
If hair loss is bothering you, book the assessment. We discuss the data, look at your pattern (Norwood scale), check ferritin and thyroid (often missed root causes), and decide whether topical-first, finasteride, or oral minoxidil makes sense.
If you're already on finasteride and worried about side effects, message a provider before stopping cold turkey. We can taper, switch to topical, or adjust the stack to match symptoms.